Navigation Links
AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
Date:4/4/2013

SOUTH SAN FRANCISCO, Calif., April 5, 2013 /PRNewswire/ -- AstraZeneca today announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA).  OSKIRA-1 had two primary endpoints: assessing signs and symptoms of RA as measured by ACR20 response rates, and an X-ray endpoint known as mTSS (modified Total Sharp Score).

In the OSKIRA-1 study, fostamatinib achieved a statistically significant improvement in ACR20 response rate at 24 weeks in both the 100 mg twice daily group and the group that received 100 mg twice daily for four weeks followed by 150 mg once daily (49%, p<0.001 and 44%, p=0.006 respectively) compared to placebo (34%). Fostamatinib did not demonstrate a statistically significant difference in mTSS compared to placebo at 24 weeks for either dose (p=0.252 and p=0.170, respectively).

The safety and tolerability findings for fostamatinib observed in the OSKIRA-1 study were generally consistent with those previously reported for the TASKi Phase 2 program. The most commonly reported adverse events were typical of those seen in earlier studies, including hypertension, diarrhea, nausea, headache and nasopharyngitis (common cold).

Briggs Morrison , MD, executive vice president of Global Medicines Development and chief medical officer, said: "These top-line results provide important information on the efficacy and safety of fostamatinib and demonstrate that the compound has an effect on the signs and symptoms of rheumatoid arthritis. We will await the results of the remaining Phase 3 studies, OSKIRA-2 and OSKIRA-3, to further evaluate and characterize the profile of fostamatinib as a potential treatment for rheumatoid arthritis."

OSKIRA-1 randomized 923 patients who had experienced an inadequate response to methotrexate (MTX) a
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
2. AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis
3. Genpact and AstraZeneca Win Outsourcing Center and SSON Awards
4. AstraZeneca Acquires Neuroscience Assets From Link Medicine
5. AstraZeneca and Leading Academic Scientists to Collaborate on Alzheimers Disease Research
6. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
7. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
8. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
9. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
10. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
11. AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... 11, 2011 MonoSol Rx, a specialty pharmaceutical ... platform, in collaboration with APR Applied Pharma Research ... FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is ... Company made the strategic decision to reacquire the ...
... 2011 Reportlinker.com announces that a new ... catalogue: Product Profiles: Systemic ... and hope to market ... order this report: ...
Cached Medicine Technology:MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 2MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 3
(Date:1/22/2015)... Bradley, Illinois (PRWEB) January 22, 2015 Deer ... -- will host a Valentine’s Day Happy Hour from 3 p.m. ... located at 12500 Regency Parkway in Huntley, Illinois, serves adults with ... Happy Hour event will include Valentine's Day treats, games and sweetheart-themed ...
(Date:1/22/2015)... Va. (PRWEB) January 22, 2015 Liberty University ... Counseling (M.A.) program from the Council for Accreditation ... program, part of Liberty’s Center for Counseling & Family ... founding dean of the university’s new School of Behavioral Sciences. ...
(Date:1/22/2015)... January 22, 2015 The City of West Hollywood ... a.m., to commemorate the 42nd anniversary of the Supreme Court decision ... “It’s been 42 years since the Roe vs. Wade decision and ... as present as ever,” said City of West Hollywood Councilmember Abbe ...
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2
... Group, Inc. will provide substantial ... revenues for the company, ... American Health Resorts, Inc. (Pink Sheets:,CAHR) of Beverly Hills, California, today ... corporate note deal valued at,approximately $8 million., With Momentum Medical ...
... ... Total Debt Reduced, BIRMINGHAM, Ala., Feb. 25 HealthSouth,Corporation (NYSE: ... the fourth quarter ended December 31, 2007. Compared to the,fourth quarter ... by 4.6% and discharges increased by,0.9%., "We are pleased with ...
... 25 Lung Cancer Alliance,(LCA) cautioned today that recently ... more people each year than all the other,major cancers ... of government statistics,entitled Cancer Facts and Figures for 2008, ... been made against cancer over the,past 15 years.", ...
... ... - ANNUAL REVENUES INCREASED 34.5% ... FFO PER SHARE UP 7.8%, NEWPORT BEACH, Calif., Feb. 25 Nationwide,Health Properties, Inc. ... investment activity., "We ended 2007 on a strong note with fourth quarter revenues up ...
... COLUMBUS, Ohio Scientists have identified the role of ... in resisting certain classes of antibiotics. , The finding ... could target bacterial resistance at its cellular source. Before ... of the activities at play in the conflict between ...
... Sunrise Senior Living,Inc. (NYSE: SRZ ) ... on March 3, 2008. Management will not be ... and explanations of,variances will be included in the ... be released before markets open., About Sunrise ...
Cached Medicine News:Health News:Vital Health Technologies, Inc. / Caribbean American Health Resorts Inc. Acquires Momentum Medical Group, Inc. 2Health News:Vital Health Technologies, Inc. / Caribbean American Health Resorts Inc. Acquires Momentum Medical Group, Inc. 3Health News:Vital Health Technologies, Inc. / Caribbean American Health Resorts Inc. Acquires Momentum Medical Group, Inc. 4Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 2Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 3Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 4Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 5Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 6Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 7Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 8Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 9Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 10Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 11Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 12Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 13Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 14Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 15Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 16Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 17Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 18Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 19Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 20Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 21Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 22Health News:'Enormous Progress' in Reducing Cancer Does Not Include Lung Cancer 2Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 2Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 3Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 4Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 5Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 6Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 7Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 8Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 9Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 10Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 11
Conducting disposable tips provide cross-contaminationfree pipetting for sensitive applications such as PCR setup....
... to optimize the accuracy and precision of ... is widely recognized by customers throughout the ... over the years and now covers a ... including filter tips, certified pure tips, stepper ...
... the Finntip Wide is designed especially for ... genomic DNA. This tip eliminates the mechanical ... excellent for use with extremely viscous liquids. ... of the orifice is 1.1 mm or ...
Capillary section fits into a 0.3-mm well for accurate loading of sequencing gels...
Medicine Products: